Study of asciminib in young adults with chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how safe and effective asciminib is for young adults with chronic myeloid leukemia (CML) in the Gulf region. It uses existing medical records to gather information, so no extra visits are needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
- You have taken asciminib between May 2023 and May 2026.
- You agree to let researchers use your medical data, or an ethics committee has approved using it without consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well asciminib works in real-world patients with chronic myeloid leukemia who have already tried at least one other treatment. It aims to see how effective and safe it is in everyday practice.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial looks at using asciminib in people with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) who are taking Scemblix. If you already use Scemblix, the study may test whether switching or adding asciminib is safe and helpful for managing your leukemia.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.